Green Leaf Pharmaceuticals: The first compound liposome innovation in China is about to enter the clinic.

The combined chemotherapy of Ilythikang combined fluorouretic is one of the first options for advanced colorectal cancer.
LY01616 is an innovative compound lipid containing both Iliticon and fluorolyn, for the treatment of advanced colorectal cancer, which is not currently available worldwide.
combined chemotherapy has become the standard solution for clinical treatment of cancer at home and abroad.
compared with single-drug chemotherapy, combined chemotherapy can use different mechanisms of action of drugs to play a synergistic role, thereby reducing the occurrence of drug resistance and improving the effect of chemotherapy.
However, the efficacy of combined chemotherapy is closely related to the proportion of the drugs used, and a specific proportion of synergies helps to achieve the best outcome.
for traditional combined chemotherapy, due to the nature of the drug itself, different metabolic pathways in the body and other reasons, so that the combination drug into the body after it is difficult to maintain the original proportion of synergy, affecting the actual efficacy.
LY01616 is to solve this clinical problem, it will be combined drugs in a specific synergetic proportion package in the same lipid body, compared with traditional combined chemotherapy methods have a number of advantages, including: 1) to a specific proportion of the drug, delivery of drugs to target tissue, better achieve the synergetic effect of combined chemotherapy;
.